Stay updated on Nivolumab & Ipilimumab in Melanoma Clinical Trial
Sign up to get notified when there's something new on the Nivolumab & Ipilimumab in Melanoma Clinical Trial page.

Latest updates to the Nivolumab & Ipilimumab in Melanoma Clinical Trial page
- CheckyesterdayNo Change Detected
- Check8 days agoChange DetectedA centralized 'Locations' section was added listing Florida, Indiana, Massachusetts, Pennsylvania, Tennessee, and Virginia, replacing the previous separate location subsections. The footer link 'HHS Vulnerability Disclosure' was removed and the page revision updated to v3.3.3.SummaryDifference0.7%

- Check15 days agoNo Change Detected
- Check22 days agoNo Change Detected
- Check37 days agoChange DetectedPubMed publication text updated to reflect auto-fill from PubMed and the revision tag updated to v3.3.2. The previous, more detailed PubMed note and revision v3.2.0 were removed.SummaryDifference0.1%

- Check44 days agoChange DetectedDeleted a general funding/operating-status notice; no study content, eligibility criteria, or results were affected.SummaryDifference0.4%

- Check58 days agoChange DetectedThe update appears to be a visual/layout refresh without any changes to the study details like the title, condition, locations, enrollment, or outcome measures. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check87 days agoChange DetectedUpdated the page to v3.2.0 with a new government-funding operating-status notice; removed the old v3.1.0 reference.SummaryDifference4%

- Check94 days agoChange DetectedCore page content updated to a new version label: from v3.0.2 to v3.1.0.SummaryDifference0.1%

Stay in the know with updates to Nivolumab & Ipilimumab in Melanoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Nivolumab & Ipilimumab in Melanoma Clinical Trial page.